Meeting
2022 ASCO Annual Meeting
Bosutinib (BOS) in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, effusion, and renal safety characterization in the BFORE trial.
Authors
Jorge E. Cortes
Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA
Jorge E. Cortes , Dragana Milojkovic , Carlo Gambacorti-Passerini , Valentin García-Gutierrez , Michael J. Mauro , Eric Leip , Simon Purcell , Andrea Viqueira , Tim H. Brümmendorf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Chronic Leukemia—CML
Clinical Trial Registration Number
NCT02130557
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7049)
DOI
10.1200/JCO.2022.40.16_suppl.7049
Abstract #
7049
Poster Bd #
280
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.
First Author: Jorge E. Cortes
Poster
2012 ASCO Annual Meeting
BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up.
First Author: Carlo Gambacorti-Passerini
Poster
2021 ASCO Annual Meeting
The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
First Author: Tim H. Brümmendorf
Poster
2022 ASCO Annual Meeting
V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
First Author: James K. McCloskey